BRPI0519515A2 - uso de antagonistas de peptÍdeo liberaÇço de bombesina/gastrina para o tratamento de condiÇÕes inflamatàrias, dano de pulmço agudo e distérbio bipolar - Google Patents

uso de antagonistas de peptÍdeo liberaÇço de bombesina/gastrina para o tratamento de condiÇÕes inflamatàrias, dano de pulmço agudo e distérbio bipolar

Info

Publication number
BRPI0519515A2
BRPI0519515A2 BRPI0519515-2A BRPI0519515A BRPI0519515A2 BR PI0519515 A2 BRPI0519515 A2 BR PI0519515A2 BR PI0519515 A BRPI0519515 A BR PI0519515A BR PI0519515 A2 BRPI0519515 A2 BR PI0519515A2
Authority
BR
Brazil
Prior art keywords
bipolar disorder
treatment
bombesin
inflammatory conditions
mania
Prior art date
Application number
BRPI0519515-2A
Other languages
English (en)
Inventor
Gilberto Schwartsmann
Rafael Roesler
Pizzol Felipe Dal
Joco Luciano Quevedo
Flavio Kapczinski
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of BRPI0519515A2 publication Critical patent/BRPI0519515A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A61K38/105—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Arc Welding In General (AREA)

Abstract

USO DE ANTAGONISTAS DE PEPTÍDEO LIBERADOR DE BOMBESINA/GASTRINA PARA O TRATAMENTO DE CONDIÇÕES INFLAMATàRIAS, DANO DE PULMçO AGUDO E DISTéRBIO BIPOLAR. A presente invenção refere-se ao uso de um antagonista de peptídeo liberador de gastrina/bombesina na preparação de uma composição farmacêutica para o tratamento de condições inflamatórias e inflamatórias mediadas-imunes, em particular sepsia, dano agudo de pulmão, e artrite reumatóide assim como para o tratamento ou profilaxia de distúrbios do cérebro, preferivelmente distúrbio bipolar, e em particular as diferentes formas e/ou subformas de distúrbio bipolar, como mania, mania aguda, mania severa, hipomania, depressão, depressão moderada, distimia, depressão severa, episódios de mania e/ou depressão, psicose/sintomas psicóticos (por exemplo, alucinações, ilusões), estado bipolar misto, distúrbio bipolar 1, distúrbio bipolar II e/ou distúrbio bipolar de ciclo rápido. Em particular, específicos nonapeptídeos com propriedades antagonistas contra bombesina ou peptídeos semelhantes à bombesina, tal como o peptídeo liberador de gastrina, podem ser usados no tratamento de condições inflamatórias e inflamatórias mediadas-imunes assim como distúrbios do cérebro.
BRPI0519515-2A 2004-12-17 2005-12-15 uso de antagonistas de peptÍdeo liberaÇço de bombesina/gastrina para o tratamento de condiÇÕes inflamatàrias, dano de pulmço agudo e distérbio bipolar BRPI0519515A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63652504P 2004-12-17 2004-12-17
US74817805P 2005-12-08 2005-12-08
PCT/EP2005/013522 WO2006063837A2 (en) 2004-12-17 2005-12-15 Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder

Publications (1)

Publication Number Publication Date
BRPI0519515A2 true BRPI0519515A2 (pt) 2009-02-25

Family

ID=35810282

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519515-2A BRPI0519515A2 (pt) 2004-12-17 2005-12-15 uso de antagonistas de peptÍdeo liberaÇço de bombesina/gastrina para o tratamento de condiÇÕes inflamatàrias, dano de pulmço agudo e distérbio bipolar

Country Status (13)

Country Link
US (1) US7795385B2 (pt)
EP (1) EP1827476B1 (pt)
JP (1) JP4950903B2 (pt)
CN (2) CN101090731B (pt)
AR (1) AR052996A1 (pt)
BR (1) BRPI0519515A2 (pt)
CA (1) CA2590804C (pt)
ES (1) ES2434943T3 (pt)
HK (1) HK1110512A1 (pt)
MX (1) MX2007007238A (pt)
NO (1) NO20073696L (pt)
TW (1) TWI361694B (pt)
WO (1) WO2006063837A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006143601A (ja) * 2004-11-16 2006-06-08 Yamato Yakuhin Kk 血液粘度低下剤
DE102007005580A1 (de) * 2007-01-23 2008-07-24 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Behandlung von Sepsis
WO2010101990A1 (en) * 2009-03-04 2010-09-10 Duke University Methods of treating lung disease and other inflammatory diseases
CN103027915A (zh) * 2011-09-29 2013-04-10 中国医学科学院基础医学研究所 氯喹治疗和氯丙嗪预防肺感染和损伤的用途
EP3849604B1 (en) * 2018-09-11 2024-05-01 University of Maryland, Baltimore Gastrin-releasing peptide (grp) inhibitors or gastrin-releasing peptide receptor (grpr) antagonists for use in treating an influenza virus infection
CN115998724B (zh) * 2023-03-28 2023-06-16 中国人民解放军军事科学院军事医学研究院 布洛芬在抗幻觉作用药物中的新用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007830A2 (en) * 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
US5244883A (en) 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
US5369094A (en) * 1990-11-29 1994-11-29 The Administrators Of The Tulane Educational Fund Polypeptide bombesin antagonists
JPH07509223A (ja) * 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
US5620955A (en) * 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
GB9322828D0 (en) * 1993-11-05 1993-12-22 Sandoz Ltd Organic compounds
JPH0853387A (ja) * 1994-08-12 1996-02-27 Sankyo Co Ltd 新規化合物ｆ−１１２６３
US5750370A (en) * 1995-06-06 1998-05-12 Human Genome Sciences, Inc. Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor
TR199900364T2 (xx) * 1996-08-22 1999-05-21 Warner-Lambert Company Peptid olmayan bombesin resept�r antagonistleri.
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
GB2369117A (en) * 2000-11-17 2002-05-22 Warner Lambert Co Bombesin receptor antagonists
GB2369118A (en) * 2000-11-17 2002-05-22 Warner Lambert Co Bombesin receptor antagonists
CA2511823A1 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors

Also Published As

Publication number Publication date
MX2007007238A (es) 2007-07-11
TWI361694B (en) 2012-04-11
CN101090731B (zh) 2012-08-08
WO2006063837A3 (en) 2007-02-08
WO2006063837A2 (en) 2006-06-22
CA2590804A1 (en) 2006-06-22
TW200635602A (en) 2006-10-16
JP2008538098A (ja) 2008-10-09
JP4950903B2 (ja) 2012-06-13
AR052996A1 (es) 2007-04-18
EP1827476A2 (en) 2007-09-05
EP1827476B1 (en) 2013-08-14
CN102441157B (zh) 2014-05-21
CN102441157A (zh) 2012-05-09
ES2434943T3 (es) 2013-12-18
HK1110512A1 (en) 2008-07-18
US20060160744A1 (en) 2006-07-20
CN101090731A (zh) 2007-12-19
CA2590804C (en) 2015-12-22
US7795385B2 (en) 2010-09-14
NO20073696L (no) 2007-09-07
WO2006063837A8 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
BRPI0519515A2 (pt) uso de antagonistas de peptÍdeo liberaÇço de bombesina/gastrina para o tratamento de condiÇÕes inflamatàrias, dano de pulmço agudo e distérbio bipolar
GT200900304A (es) "antagonistas ciclicos de peptido cxcr4"
DOP2010000097A (es) Anticuerpos especificos para la forma de protofibrillas de la proteina beta-amiloide
IS8669A (is) Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
UY32341A (es) Proteínas de unión antígeno novedosas
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
AR035392A1 (es) Moduladores del receptor de adenosina
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
BR112012021337A2 (pt) formulações de apixaban.
IT1362675B (it) N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
CL2008003197A1 (es) Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer.
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
MX2009009320A (es) Uso de antagonistas de lhrh para el tratamiento de sintomas del tracto urinario inferior, en particular vejiga hiperactiva y/o hiperactividad detrusora.
UY31530A (es) "poliaminas reticuladas y sus usos en composiciones farmacéuticas"
WO2013160317A3 (en) Crhr1 antagonists for use in the treatment of patients having crh overactivity
CL2008002411A1 (es) Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras.
AR057239A1 (es) Inmunoglobulinas
WO2007061692A3 (en) Spirolactam tricyclic cgrp receptor antagonists
CL2004001251A1 (es) Compuestos derivados de imidazol-piridazinas, bloqueadores del receptor nmda, composicion farmaceutica que los contiene, procedimiento de preparacion y su uso en el tratamiento de enfermedades neurodegenerativas tales como alzheimer, parkinson, enfer
BR112013032977A2 (pt) ferramenta de aperto temporário multieixo
CA2744339A1 (en) Method for treating parkinson's disease
WO2007045705A3 (es) Compuestos para el tratamiento de la fibrilación auricular
WO2010077867A3 (en) Treating idiopathic thrombocytopenic purpura with compositions comprising extracts of astragalus membranaceus
CL2007003556A1 (es) Compuestos derivados de 6-(piperidin-4-ilamino)piridazin-3-carbonitrilos, antagonistas del receptor de dopamina 2 de rapida disociacion; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: AETERNA ZENTARIS GMBH (DE)

Free format text: ALTERADO DE: ZENTARIS GMBH

B25A Requested transfer of rights approved

Owner name: BEXAR GLOBAL INC. (AR)

Free format text: TRANSFERIDO DE: AETERNA ZENTARIS GMBH

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A, ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]